| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1041373421 |
| P356 | DOI | 10.2165/00003088-200140030-00004 |
| P698 | PubMed publication ID | 11327198 |
| P2093 | author name string | Cutler NR | |
| Crawford AW | |||
| Jhee SS | |||
| Shiovitz T | |||
| P2860 | cites work | Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90) | Q28256565 |
| Headache recurrence after subcutaneous sumatriptan and early treatment | Q28327716 | ||
| Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors | Q28373188 | ||
| Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence | Q28376494 | ||
| Sumatriptan is effective in the treatment of menstrual migraine: a review of prospective studies and retrospective analyses | Q33547343 | ||
| Naratriptan: an alternative for migraine | Q33689204 | ||
| Migraine: a comprehensive review of new treatment options | Q33715929 | ||
| Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies | Q33792830 | ||
| Cardiovascular safety of 5HT1B/1D agonists--is there a cause for concern? | Q34481198 | ||
| The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers | Q34738942 | ||
| The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). | Q34741307 | ||
| Selective 5-HT1D alpha serotonin receptor gene expression in trigeminal ganglia: implications for antimigraine drug development | Q35189866 | ||
| The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers | Q35802614 | ||
| Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers | Q36053366 | ||
| The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers | Q36053563 | ||
| The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90) | Q36094218 | ||
| Mode of action of the anti-migraine drug sumatriptan | Q36465525 | ||
| Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. | Q36723711 | ||
| The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache | Q36905403 | ||
| Pharmacokinetics of rizatriptan tablets during and between migraine attacks | Q39372579 | ||
| Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison | Q39417816 | ||
| Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group | Q39420231 | ||
| Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group | Q39420238 | ||
| A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine | Q39431252 | ||
| Patient preference for oral sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: a double-blind, randomized, crossover study. Sumatriptan Tablets S2CM11 Study Group. | Q39432404 | ||
| Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine | Q39435550 | ||
| Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study | Q39439890 | ||
| Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat | Q39443442 | ||
| Tolerability and efficacy of naratriptan tablets with long-term treatment (6 months). Naratriptan Long-term Study Group | Q39447979 | ||
| Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group | Q39448143 | ||
| Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan | Q39448906 | ||
| Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Naratriptan S2WA3001 Study Group | Q39451379 | ||
| Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. The Naratriptan S2WA3003 Study Group | Q39451910 | ||
| Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies | Q39452003 | ||
| Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group | Q39452008 | ||
| Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group | Q39461354 | ||
| Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice | Q39463122 | ||
| A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine | Q39463497 | ||
| Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience | Q39471681 | ||
| The safety of concomitant use of sumatriptan and antidepressant treatments | Q39475958 | ||
| Sumatriptan clinical pharmacokinetics | Q40589845 | ||
| Serotonin (5-HT) and migraine | Q40633746 | ||
| Clinical and experimental effects of sumatriptan in humans | Q40855384 | ||
| Side effects of ergotamine | Q41126543 | ||
| Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients | Q41289268 | ||
| Sumatriptan contraindications and the serotonin syndrome. | Q41707189 | ||
| Lack of an interaction between propranolol and sumatriptan | Q42129047 | ||
| Naratriptan: biological profile in animal models relevant to migraine | Q42549327 | ||
| Permeation of sumatriptan through human vaginal and buccal mucosa | Q46652580 | ||
| Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries | Q47698318 | ||
| Migraine polypharmacy and the tolerability of sumatriptan: a large-scale, prospective study | Q48089043 | ||
| Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? | Q48896233 | ||
| Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study. | Q50868159 | ||
| The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women. | Q50896559 | ||
| No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis. | Q50918652 | ||
| Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. | Q53339904 | ||
| Effect of subcutaneous naratriptan on forearm blood flow. | Q53350815 | ||
| Effect of hepatic impairment on the pharmacokinetics of zolmitriptan. | Q53946789 | ||
| The clinical pharmacokinetics of zolmitriptan. | Q54394241 | ||
| Comparison of the Efficacy of Zolmitriptan and Sumatriptan: Issues in Migraine Trial Design | Q57024741 | ||
| Oral sumatriptan in acute migraine | Q58619528 | ||
| Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group | Q68241898 | ||
| The Clinical Pharmacology, Pharmacokinetics and Metabolism of Sumatriptan | Q68252114 | ||
| Sumatriptan--an oral dose-defining study. The Oral Sumatriptan Dose-Defining Study Group | Q68252118 | ||
| Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group | Q68252122 | ||
| Cephalic hyperemia during migraine headaches. A prospective study | Q69642768 | ||
| How does sumatriptan perform in clinical practice? | Q71372255 | ||
| Distribution and excretion of sumatriptan in human milk | Q71675382 | ||
| Pharmacokinetics and food interaction of MK-462 in healthy males | Q71964042 | ||
| Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan | Q71980834 | ||
| Lack of Pharmacokinetic Interaction Between Butorphanol Tartrate Nasal Spray and Sumatriptan Succinate | Q71997318 | ||
| Single dose pharmacokinetics of sumatriptan in healthy volunteers | Q72281602 | ||
| Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver | Q72371152 | ||
| Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans | Q73302256 | ||
| Lack of pharmacokinetic interaction between sumatriptan and naproxen | Q73345826 | ||
| Eletriptan and coronary artery | Q73604680 | ||
| Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers | Q73820770 | ||
| Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group | Q73884479 | ||
| A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group | Q77332487 | ||
| Effects of subcutaneous naratriptan on systemic and pulmonary haemodynamics and coronary artery diameter in humans | Q78020306 | ||
| Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan | Q93927625 | ||
| P433 | issue | 3 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| pharmacodynamics | Q725307 | ||
| P304 | page(s) | 189-205 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review | |
| P478 | volume | 40 |
| Q47548932 | 17-β-Estradiol induces spreading depression and pain behavior in alert female rats |
| Q44805088 | A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy adolescents and adults |
| Q80497004 | A unique iontophoretic patch for optimal transdermal delivery of sumatriptan |
| Q54443866 | Adding NSAIDs to triptans: could less be more? |
| Q39365280 | Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial |
| Q37129812 | Almotriptan in the treatment of migraine. |
| Q28216921 | Almotriptan: a review of its use in migraine |
| Q44043945 | Alpha[11C] methyl-L-typtophan positron emission tomography in patients with alternating hemiplegia of childhood. |
| Q44051817 | CNS effects of sumatriptan and rizatriptan in healthy female volunteers. |
| Q28239382 | Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine |
| Q35982145 | Clinical profile and practice experience of almotriptan |
| Q46076879 | Cytochrome P450 and Non-Cytochrome P450 Oxidative Metabolism: Contributions to the Pharmacokinetics, Safety, and Efficacy of Xenobiotics |
| Q39406672 | Dose range-finding studies with frovatriptan in the acute treatment of migraine |
| Q38378898 | Drug safety in acute migraine treatment. |
| Q89997982 | Economic burden of migraine in Latvia and Lithuania: direct and indirect costs |
| Q39162721 | Effect of N-salicyloyltryptamine (STP), a novel tryptamine analogue, on parameters of cell viability, oxidative stress, and immunomodulation in RAW 264.7 macrophages. |
| Q44700406 | Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain |
| Q39276728 | Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders |
| Q33671824 | Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura |
| Q28074159 | Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response |
| Q36641480 | Eletriptan: a review and new perspectives |
| Q36514170 | Eletriptan: a review of its use in the acute treatment of migraine |
| Q37818258 | Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy |
| Q43967358 | Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan |
| Q44171192 | In the pipeline. Triptans--new developments |
| Q34775667 | Indolealkylamines: biotransformations and potential drug-drug interactions |
| Q36373560 | Infrequent or non-response to oral sumatriptan does not predict response to other triptans--review of four trials |
| Q37271453 | Longitudinal changes in neurodevelopmental outcomes between 18 and 36 months in children with prenatal triptan exposure: findings from the Norwegian Mother and Child Cohort Study |
| Q34633457 | Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir |
| Q42122554 | Method development and validation of almotriptan in human plasma by HPLC tandem mass spectrometry: application to pharmacokinetic study. |
| Q49873285 | Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action |
| Q54480739 | Naratriptan mitigates CGRP1-associated motor neuron degeneration caused by an expanded polyglutamine repeat tract. |
| Q57988151 | OCT1 mediates hepatic uptake of sumatriptan and loss-of-functionOCT1polymorphisms affect sumatriptan pharmacokinetics |
| Q36978875 | Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment |
| Q39338847 | Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan |
| Q50350695 | Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects |
| Q45040981 | Pharmacokinetics of frovatriptan in adolescent migraineurs |
| Q34481166 | Preclinical neuropharmacology of naratriptan. |
| Q41500403 | Preparation and evaluation of tubular micelles of pluronic lecithin organogel for transdermal delivery of sumatriptan |
| Q34136456 | Rizatriptan: an update of its use in the management of migraine |
| Q91709999 | Sex-Specific Pharmacotherapy for Migraine: A Narrative Review |
| Q42738044 | Sublingual Delivery of Frovatriptan: An Indication of Potential Alternative Route. |
| Q38949801 | The influence of genetic constitution on migraine drug responses |
| Q39983756 | The triptans |
| Q35011915 | Therapies in development for the treatment of migraine |
| Q35048015 | Tolerability of the triptans: clinical implications |
| Q34619206 | Transdermal delivery of sumatriptan for the treatment of acute migraine |
| Q34375878 | What do patients want from acute migraine treatment? |
| Q44171184 | What takes place in the receptor? Ligand-receptor interaction in 5-HT agonists |
Search more.